

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Docket No.: POUSTKA-2

In re Application of:

ANNEMARIE POUSTKA et al.

Cont. of Appl. No.: PCT/DE99/03982

Int. Filing Date: December 14, 1999

For: METHOD AND DEVICES FOR APPLYING  
SUBSTANCES TO A SUPPORT,  
ESPECIALLY MONOMERS FOR THE  
COMBINATORIAL SYNTHESIS OF  
MOLECULE LIBRARIES

#4  
PY  
11-7-01  
11002 U.S. PRO  
09/880688  
06/13/01

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Express Mail mailing label number: **EL 822863733 US**

Date of Deposit: **June 13, 2001**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

**ANTONELLA FUSILLO**

[Name of person mailing paper or fee]

*Antonella Fusillo*

[Signature]

S I R:

In accordance with 37 C.F.R. 1.56, applicant wishes to call the attention of the Examiner to the following references A) to E) which were cited in the International Search Report issued by the European Patent Office with regard to the corresponding international patent application No. PCT/DE99/03982. Applicant does not admit that any of the cited documents constitutes prior art against the pending application.

	Country:	Patent or Appl. No:	Patentee or Applicant:	Issue or Filing Date:
A)	PCT	WO 98/12559 A	J P Demers	03-26-98
B)	USA	US 5 449 754 A	Nishioka	09-12-95
C)	PCT	WO 99/52625 A	Institut f. Diagno.	10-21-99
D)	PCT	WO 97/44134 A	Incyte Pharma.	11-27-97
E)	PCT	WO 00/15653 A	Central Research L.	03-23-00

Copies of these references are submitted herewith along with form PTO-1449. The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

☐ This Information Disclosure Statement is filed within three months of the filing date of a national application other than a continued prosecution application under 1.53(d), so that no fee under 37 C.F.R. §1.97 is due.

☐ This Information Disclosure Statement is filed within three months of the date of entry of the national stage as set forth in 1.491 in an international application, so that no fee under 37 C.F.R. §1.97 is due.

☒ This Information Disclosure Statement is filed before the mailing of a first Office Action on the merits, so that no fee under 37 C.F.R. §1.97 is due.

☐ This Information Disclosure Statement is filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114, so that no fee under 37 C.F.R. §1.97 is due.

☐ This Information Disclosure Statement is filed after the issuance of a first office but before issuance of a final action under §1.113, or a notice of allowance under §1.311.

☐ This Information Disclosure Statement is submitted after the mailing of a final action or a notice of allowance, but before payment of the issue fee.

☐ The undersigned submits the following statement requesting consideration of this statement:

The undersigned hereby states:

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement;

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

☐ The fee of \$180.00 set forth in 1.17(p).

☐ The Commissioner is hereby authorized to charge the fee as set forth in 1.17(p), and any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

In order to satisfy the requirement under 37 C.F.R. §1.98(a)(3) for a concise explanation of the relevance of each item of information, applicant herewith submits a copy of the International Search Report together with a translation of the relevant pages thereof.

The above-identified application discloses and claims an invention patentable over this prior art.

Entry of the references above set forth into the file of the above application is believed to be in order and is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

Respectfully submitted

By: 

Henry M. Feiereisen  
Agent for Applicant  
Reg. No. 31,084

Date: June 13, 2001  
350 Fifth Avenue  
Suite 3220  
New York, N.Y. 10118  
(212) 244-5500  
HMF:af

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark Office**INFORMATION DISCLOSURE CITATION**

<b>Attorney's Docket No.</b>  <b>POUSTKA-2</b>	<b>Applicant</b>  <b>ANNEMARIE POUSTKA et al.</b>	<b>Cont. of Appl. No.</b>  <b>PCT/DE99/03982</b>
<b>Int. Filing Date</b>  <b>December 14, 1999</b>	<b>Group</b>	<b>Examiner</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date, if appropriate
	5,449,754 A	09-12-95	Nishioka			

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation
	WO 98/12559 A	03-26-98	PCT			YES
	WO 99/52625 A	10-21-99	PCT			Abstract
	WO 97/44134 A	11-27-97	PCT			Yes
	WO 00/15653 A	03-23-00	PCT			Yes

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

<b>Examiner:</b>	<b>Date considered:</b>	

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.